Aarti Drugs Ltd
Pharmaceuticals & Biotechnology | Small Cap
Aarti Drugs Ltd demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid foundation and efficient management of assets. Its coverage ratios also reflect a robust ability to meet its financial obligations. However, the company faces challenges in liquidity, efficiency, and growth. Decreasing revenue, operating profit, and EPS growth suggest potential market pressures or internal inefficiencies. Low liquidity ratios implies the company might face difficulty in meeting its short-term obligations. While the company's asset growth is a positive sign, its overall financial health is moderate due to the mentioned weaknesses.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsUndervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.80
- Financial Ratio2.40
- Profitability Ratio10.00
- Efficiency Ratio3.00
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio4.26
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Aarti Drugs Ltd demonstrates a mixed financial performance. The company exhibits strong solvency and profitability, indicating a solid foundation and efficient management of assets. Its coverage ratios also reflect a robust ability to meet its financial obligations. However, the company faces challenges in liquidity, efficiency, and growth. Decreasing revenue, operating profit, and EPS growth suggest potential market pressures or internal inefficiencies. Low liquidity ratios implies the company might face difficulty in meeting its short-term obligations. While the company's asset growth is a positive sign, its overall financial health is moderate due to the mentioned weaknesses.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
19.98
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
17.34
P/B RATIO
2.18
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.43
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
-2.48
EV/EBITDA RATIO
12.52
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹370.35 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤3rd Feb 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
The growth metrics present a mixed picture, with strong asset growth offset by declines in revenue, operating profit, and EPS. This indicates potential challenges in translating asset growth into profitable revenue streams. Focus on strategic investments and market expansion could help improve overall growth. A positive growth rate is generally preferred.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 15.5 | 9.12 | -6.89 | -5.61 | 7.46 |
| Operating Profit Growth Rate | -24.32 | -7.21 | 3.88 | -9.66 | 6.55 |
| Earnings Per Share (EPS) Growth | -26.42 | -18.88 | 3.84 | -1.23 | 15.96 |
| Asset Growth Rate | 25.03 | 9.65 | 0.45 | 5.88 | 9.32 |
| Net Income Growth Rate | -26.79 | -19.02 | 3.61 | -2.33 | 16.07 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial metrics indicate challenges in key areas such as earnings per share, book value, and capital expenditures. Low adjusted EPS and cash EPS suggest potential profitability issues, while a low book value per share may reflect limited equity value. Careful management of capital expenditures is necessary to ensure efficient resource allocation. Higher values for EPS and Book Value are generally preferred.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 22.04 | 17.85 | 18.7 | 18.46 | 21.43 |
| Cash Earnings Per Share (Cash EPS) | 27.42 | 23.23 | 24.24 | 24.62 | 28.79 |
| Book Value Per Share | 111.51 | 128.28 | 139.35 | 150.44 | 170.22 |
| Dividend Per Share (DPS) | 1.11 | 1.08 | 0.93 | 0.92 | 0 |
| Capital Expenditures (CapEx) | 152 | 165 | 226 | 177 | 173 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability metrics demonstrate strong performance across various measures. High gross profit margins, ROCE, ROE, ROA, operating margin, and net margin indicate efficient operations and effective cost management. Maintaining these profitability levels is crucial for long-term success. Higher values for all the profitability ratios are generally preferred.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.37 | 9.54 | 10.68 | 9.8 | 9.43 |
| Return on Capital Employed (ROCE) | 21 | 15 | 15 | 13 | 12 |
| Return on Equity (ROE) | 19.77 | 13.91 | 13.42 | 12.27 | 12.59 |
| Return on Assets (ROA) | 15.08 | 12.76 | 13.2 | 11.26 | 10.98 |
| Operating Margin | 13.38 | 11.38 | 12.69 | 12.15 | 12.05 |
| Net Margin | 8.24 | 6.11 | 6.8 | 7.04 | 7.6 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency metrics point towards inefficiencies in asset utilization and working capital management. Low turnover ratios and extended collection periods suggest that the company is not effectively leveraging its assets to generate revenue. Addressing these inefficiencies can improve profitability and free up capital for reinvestment. Higher turnover ratios are typically preferred as they indicate efficient use of assets for generating revenue.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.61 | 4.02 | 3.12 | 2.76 | 2.36 |
| Inventory Turnover Ratio | 4.69 | 4.72 | 4.51 | 4.49 | 4.82 |
| Receivables Turnover Ratio | 3.81 | 3.36 | 3.22 | 3.28 | 3.24 |
| Days Sales in Inventory Ratio | 77.83 | 77.33 | 80.93 | 81.29 | 75.73 |
| Receivable Days | 95.8 | 108.63 | 113.35 | 111.28 | 112.65 |
| Capital Turnover Ratio | 2.11 | 1.94 | 1.62 | 1.44 | 1.42 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios demonstrate a strong ability to meet interest and dividend obligations. High-interest coverage indicates a comfortable margin for servicing debt, while a high equity dividend coverage suggests a strong capacity to reward shareholders. This provides financial flexibility and reduces the risk of financial distress. A higher value is generally preferred for both the ratios.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 12.25 | 7.05 | 7.21 | 6.44 | 7.21 |
| Equity Dividend Coverage Ratio | 20 | 16.67 | 20 | 20 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The solvency position indicates strong financial stability and a low risk of financial distress. Conservative debt levels and a high proportion of equity in the capital structure provide a solid foundation for long-term sustainability. This allows the company to pursue growth opportunities without undue financial strain. A lower debt ratio is generally preferred as it indicates lesser dependence on borrowed funds.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.12 | 0.15 | 0.18 | 0.17 | 0.14 |
| Debt to Equity Ratio | 0.14 | 0.18 | 0.22 | 0.2 | 0.16 |
| Equity Ratio | 0.88 | 0.85 | 0.82 | 0.83 | 0.86 |
| Debt To Asset Ratio | 0.06 | 0.09 | 0.11 | 0.11 | 0.09 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position indicates challenges in meeting short-term obligations. While the quick ratio suggests an ability to cover immediate liabilities, low cash and operating cash flow ratios raise concerns about the availability of liquid assets. This necessitates careful monitoring of working capital to ensure operational needs are met. The current ratio indicates the company's ability to pay its short term obligation with its current assets. A higher current ratio indicates better liquidity position of the company.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.38 | 1.48 | 1.53 | 1.48 | 1.48 |
| Quick Ratio | 0.87 | 0.98 | 0.98 | 0.96 | 0.99 |
| Cash Ratio | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Operating Cash Flow Ratio | 0.07 | 0.13 | 0.41 | 0.27 | 0.25 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 6 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 7 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 8 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 9 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 10 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 11 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 12 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 13 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 14 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 15 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 16 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 17 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
| 19 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
The management of Aarti Drugs demonstrates a mixed performance. Strengths include consistent dividend payouts and relatively stable operating profit margins. However, there are notable weaknesses such as declining sales and profit growth, along with decreasing promoter holding. Increased debt levels also impact financial leverage. Overall, the management's effectiveness is mixed, suggesting areas needing improvement in growth and financial strategies.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Dividend Payout % | 5% | Consistent sharing of profits |
| OPM % (Avg) | 12% | Stable operating profit margin | |
| CONS | Sales Growth (3Y) | -1% | Declining sales growth |
| Profit Growth (3Y) | -6% | Declining profit growth | |
| Promoter Holding | 55.48% | Decreasing promoter confidence | |
| Debt/Equity Ratio | 0.45 | Increased financial leverage |
Financial Performance & Growth
Aarti Drugs' financial performance reveals a decelerating trend in growth. The compounded sales growth has declined over the years, with a 3-year CAGR of -1% and a TTM sales growth of -6%. Profit growth has also slowed, indicated by a 3-year compounded growth of -6% and a TTM growth of -2%.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Compounded Sales Growth | 13.1% | 16.9% | 9.14% | -6.90% | -5.60% |
| Compounded Profit Growth | 14.1% | 38.2% | -26.1% | 3.6% | -2.3% |
Capital Efficiency & Returns
The Return on Capital Employed (ROCE) and Return on Equity (ROE) reflect moderate capital efficiency. The current ROCE stands at 13.70%, while the current ROE is 12.39%. Historical data illustrates fluctuations in these metrics, suggesting variability in generating returns on capital and equity.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Average ROCE | 17.3% | 25.3% | 15% | 15% | 13% |
| Average ROE | 18.3% | 20.2% | 14.2% | 14.9% | 14.4% |
Financial Health & Prudence
Aarti Drugs' financial health indicates a rise in debt levels. Total borrowings have increased from ₹351 Cr in Mar 2021 to ₹615 Cr in Mar 2025, impacting the Debt/Equity ratio. The company has maintained a consistent dividend payout, sharing profits with shareholders.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Borrowings | ₹351 Cr | ₹543 Cr | ₹609 Cr | ₹564 Cr | ₹615 Cr |
| Debt/Equity Ratio | 0.43 | 0.53 | 0.49 | 0.45 | 0.45 |
| Dividend Payout % | 8% | 5% | 6% | 5% | 5% |
Shareholding & Ownership Structure
The shareholding pattern reveals a decreasing trend in promoter holding. Promoter holding has decreased from 60.20% in Mar 2021 to 55.48% in Mar 2025. Conversely, DII holding has increased, indicating rising institutional interest.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding | 60.20% | 59.83% | 59.57% | 57.13% | 55.48% |
| FII Holding | 2.99% | 2.07% | 1.94% | 2.56% | 2.25% |
| DII Holding | 1.76% | 2.69% | 4.09% | 5.99% | 9.70% |
Aarti Drugs faces moderate risk due to increasing debt and decreasing sales and profit growth, potentially leading to financial strain. However, a consistent dividend payout and stable operational efficiency offer some stability. Monitoring financial leverage and strategic responses to growth challenges are essential to mitigate risks.
Accounting quality red flags
The increase in 'Other Income' from ₹4 Cr in Mar 2024 to ₹16 Cr in Mar 2025 merits scrutiny. A significant portion of profit from non-core activities could suggest underlying operational issues.
Segment performance volatility
Quarterly results show fluctuations in sales and profit growth. YOY Sales Growth % varies from 38.37% in Mar 2022 to -16.49% in Mar 2024, while YOY Profit Growth % fluctuates from 38% in Jun 2023 to -31% in Jun 2024. These fluctuations indicate instability in segment performance.
Foreign exchange or interest rate exposure
Interest expenses have remained relatively stable, with ₹26 Cr in Mar 2021 and ₹36 Cr in Mar 2025. An increase in debt levels could amplify the impact of interest rate fluctuations, posing a risk to profitability.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10371.32Bearish
- SMA 20371.20Bearish
- SMA 50371.43Bearish
- EMA 10370.96Bearish
- EMA 20371.36Bearish
- EMA 50372.27Bearish
- DEMA 10370.31Bearish
- DEMA 20370.88Bearish
- DEMA 50370.29Bearish
- TEMA 10369.85Bullish
- TEMA 20370.69Bearish
- TEMA 50370.83Bearish
- MACD-0.42Bearish
- ADX21.44Weak Trend
- IndicatorValueSignal
- RSI46.29Neutral
- CCI-28.00Neutral
- ROC 9-1.07Bearish
- ROC 140.68Bullish
- ROC 25-0.59Bearish
- Stoch K20.16Neutral
- Stoch D19.36Oversold
- IndicatorValueSignal
- BB Upper376.68Neutral
- BB Middle371.20Neutral
- BB Lower365.72Neutral
- ATR3.44Low Volatility
- IndicatorValueSignal
- MFI42.61Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10370.69Bearish
- SMA 20371.57Bearish
- SMA 50372.89Bearish
- EMA 10370.75Bearish
- EMA 20371.23Bearish
- EMA 50373.41Bearish
- DEMA 10370.34Bearish
- DEMA 20370.14Bearish
- DEMA 50370.12Bearish
- TEMA 10370.26Bearish
- TEMA 20370.58Bearish
- TEMA 50368.56Bullish
- MACD-0.78Bullish
- ADX20.28Weak Trend
- IndicatorValueSignal
- RSI46.70Neutral
- CCI-51.98Neutral
- ROC 90.61Bullish
- ROC 14-0.35Bearish
- ROC 250.56Bullish
- Stoch K18.26Oversold
- Stoch D22.72Neutral
- IndicatorValueSignal
- BB Upper376.40Neutral
- BB Middle371.57Neutral
- BB Lower366.73Neutral
- ATR4.58Low Volatility
- IndicatorValueSignal
- MFI45.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10371.02Bearish
- SMA 20371.27Bearish
- SMA 50377.19Bearish
- EMA 10370.61Bearish
- EMA 20372.12Bearish
- EMA 50374.33Bearish
- DEMA 10369.52Bullish
- DEMA 20369.11Bullish
- DEMA 50374.92Bearish
- TEMA 10369.89Bullish
- TEMA 20368.70Bullish
- TEMA 50N/AN/A
- MACD-2.13Bullish
- ADX15.00Weak Trend
- IndicatorValueSignal
- RSI46.03Neutral
- CCI-62.21Neutral
- ROC 9-0.82Bearish
- ROC 14-0.67Bearish
- ROC 25-1.45Bearish
- Stoch K23.35Neutral
- Stoch D27.02Neutral
- IndicatorValueSignal
- BB Upper377.81Neutral
- BB Middle371.27Neutral
- BB Lower364.73Neutral
- ATR7.21Low Volatility
- IndicatorValueSignal
- MFI59.40Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10370.84Bearish
- SMA 20377.61Bearish
- SMA 50375.26Bearish
- SMA 100368.38Bullish
- SMA 200412.15Bearish
- EMA 10371.96Bearish
- EMA 20374.11Bearish
- EMA 50373.90Bearish
- EMA 100379.67Bearish
- EMA 200398.39Bearish
- DEMA 10369.20Bullish
- DEMA 20372.06Bearish
- DEMA 50373.68Bearish
- DEMA 100361.17Bullish
- DEMA 200365.76Bullish
- TEMA 10368.92Bullish
- TEMA 20368.44Bullish
- TEMA 50379.78Bearish
- TEMA 100367.18Bullish
- TEMA 200354.72Bullish
- MACD-1.90Bearish
- ADX11.89Weak Trend
- IndicatorValueSignal
- RSI46.51Neutral
- CCI-70.86Neutral
- ROC 14-3.28Bearish
- ROC 252.21Bullish
- Stoch K19.06Oversold
- Stoch D17.50Oversold
- IndicatorValueSignal
- BB Upper394.94Neutral
- BB Middle377.61Neutral
- BB Lower360.29Neutral
- ATR11.47Low Volatility
- IndicatorValueSignal
- MFI57.27Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20367.20Bullish
- SMA 50424.87Bearish
- EMA 20378.26Bearish
- EMA 50403.01Bearish
- DEMA 20362.61Bullish
- DEMA 50370.18Bullish
- TEMA 20369.67Bullish
- TEMA 50357.72Bullish
- MACD-9.62Bullish
- ADX10.09Weak Trend
- IndicatorValueSignal
- RSI45.22Neutral
- CCI-63.28Neutral
- ROC 144.09Bullish
- ROC 25-2.58Bearish
- Stoch K65.00Neutral
- Stoch D69.82Neutral
- IndicatorValueSignal
- BB Upper396.86Neutral
- BB Middle367.20Neutral
- BB Lower337.55Neutral
- ATR26.71Low Volatility
- IndicatorValueSignal
- MFI60.28Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6372.69Bullish
- SMA 12422.75Bearish
- SMA 24436.63Bearish
- EMA 6381.23Bearish
- EMA 12401.32Bearish
- EMA 24424.66Bearish
- DEMA 6361.70Bullish
- DEMA 12371.38Bullish
- DEMA 24394.14Bearish
- TEMA 6361.77Bullish
- TEMA 12360.63Bullish
- TEMA 24370.44Bullish
- MACD-6.85Bearish
- ADX13.60Weak Trend
- IndicatorValueSignal
- RSI47.52Neutral
- CCI-100.58Oversold
- ROC 25-24.61Bearish
- ROC 50-11.35Bearish
- Stoch K33.36Neutral
- Stoch D36.01Neutral
- IndicatorValueSignal
- BB Upper530.76Neutral
- BB Middle418.42Neutral
- BB Lower306.07Neutral
- ATR71.69Low Volatility
- IndicatorValueSignal
- MFI72.69Neutral